Iovance Biotherapeutics' stock fell 46% following a downgrade to Hold due to over-optimism in its valuation. While the melanoma drug AMTAGVI (lifileucel) is gaining market traction, the potential for its use in non-small cell lung cancer (NSCLC) appears overestimated based on recent data showing a 24.6% overall response rate, slightly below earlier expectations. However, genomic subgroup analysis in NSCLC suggests some promising areas that could support lifileucel's future in this indication. The downgrade reflects caution amid mixed clinical signals and valuation concerns.
As of Nov 06, 2026 20:41 WIB, Iovance Biotherapeutics (IOVA) shares are trading at USD 7.92 on Pluang, showing a 1-day gain of 2.33%. The stock has a market capitalization of $3.49 billion and an enterprise value of $3.42 billion. Notably, Pluang users currently place 100% of their orders as buys, reflecting strong buying interest despite recent valuation concerns.
